EA6141
OPEN TO ACCRUAL
PII/III Study of Nivo+ Ipi + Sargramostim vs. Nivo + Ipi in Pts w/ Stage III/IV Melanoma
NCI10285
OPEN TO ACCRUAL
Ph I/II EZH2 inhibitor w/BRAF/MEK inhibition in BRAF mutated metastatic melanoma who progressed
UW22043
OPEN TO ACCRUAL
Phase 1 Study of FF-10850, Topotecan Liposome Injection, in Advanced Solid Tumors
UW22142
OPEN TO ACCRUAL
Feasibility of using TRAQinform Immuno for Melanoma Treatment Decisions
UW23071
OPEN TO ACCRUAL
AU-011-301
UW23077
OPEN TO ACCRUAL
Correlating Early FDG PET/CT and ctDNA in ICI-Treated Melanoma Patients
UW24053
OPEN TO ACCRUAL
SEACRAFT-2: Naporafenib + Trametinib vs MD Choice for NRAS Mutant Unresectable/Metastatic Melanoma
UW24061
OPEN TO ACCRUAL
Ph 3 Study w/Combo of Fianlimab+Cemiplimab vs Relatlimab+Nivo in Participants w/Metastatic Melanoma